Tag Archives: HER2-Low Breast Cancer
FDA Approves First Targeted Therapy to Treat HER2-Low Breast Cancer
On August 05, 2022, the U.S. FDA approved Enhertu (T-DXd) or (trastuzumab deruxtecan), an IV infusion to treat patients with […]
On August 05, 2022, the U.S. FDA approved Enhertu (T-DXd) or (trastuzumab deruxtecan), an IV infusion to treat patients with […]
